Johnson & Johnson

Yahoo Finance • 14 hours ago

Should You Forget Johnson & Johnson and Buy This Magnificent High-Yield Dividend Stock Instead?

Key Points Johnson & Johnson is a Dividend King. The stock offers an attractive 3.4% dividend yield. Another healthcare stock has a 7.4% yield and four decades of annual dividend increases behind it. Johnson & Johnson(NYSE: JNJ) is a sto... Full story

Yahoo Finance • 21 hours ago

How AbbVie is Engineering Its Next Growth Phase

AbbVie (NASDAQ:ABBV) has emerged as one of the standout performers in the healthcare sector this year, with its stock climbing 6% while the broader S&P 500 healthcare index declined 1%. This outperformance reflects investor confidence in t... Full story

Yahoo Finance • 4 days ago

North America Beta-Glucan Market Forecast and Company Analysis Report 2025-2033 Featuring Koninklijke Philips, EDAP TMS, Johnson & Johnson, Medtronic, Hitachi, Theraclion, Stryker, and GE

Company Logo The North America Beta Glucan Market, valued at USD 204.03 million in 2024, is poised to grow to USD 373.85 million by 2033, with a CAGR of 6.96% from 2025 to 2033. This growth is driven by rising consumer demand for immune-b... Full story

Yahoo Finance • 4 days ago

Goldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy Tailwinds

Johnson & Johnson (NYSE:JNJ) ranks among the best set-it-and-forget-it stocks to buy. Asad Haider, a Goldman Sachs analyst, remained optimistic about Johnson & Johnson (NYSE:JNJ) shares, rating it as a Buy on June 5. The analyst noted seve... Full story

Yahoo Finance • 4 days ago

Johnson & Johnson submits application to the European Medicines Agency seeking indication extension of AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of adult patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations

Janssen Cilag International NV The submission is based on results from the Phase 3 AMPLITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisone or prednisolone compared to a current standard of care, abirat... Full story

Yahoo Finance • 5 days ago

Leaked memo reportedly shows biotech lobby group’s opposition to RFK Jr.

[HHS Secretary Robert F. Kennedy Jr. Testifies During House Hearing] Kayla Bartkowski/Getty Images News One of the leading lobby groups of the biotech industry, Biotechnology Innovation Organization (BIO), has named HHS Secretary Robert F... Full story

Yahoo Finance • 5 days ago

US FDA approves Regeneron's blood cancer therapy

By Puyaan Singh (Reuters) -Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood cancer called multiple myeloma that has recurred in patients who had received at least... Full story

Yahoo Finance • 6 days ago

US judge halts Trump administration move to layoff HHS employees

[US Department of Health and Human Services] MarioGuti/iStock via Getty Images A U.S. federal judge has put a stop to the Trump administration's plans to significantly downsize the workforce and close several agencies within the U.S. Depa... Full story

Yahoo Finance • 7 days ago

PJM Appoints Deena O'Brien as Senior Director of Communications

VALLEY FORGE, Pa., June 30, 2025 /PRNewswire/ -- PJM Interconnection has appointed Deena O'Brien as senior director of corporate communications with responsibility for external and internal communications, creative services, PJM's online p... Full story

Yahoo Finance • 7 days ago

US FDA eliminates risk evaluation, mitigation strategies for CAR-T cancer therapies (June 27)

(Corrects paragraph 4 in June 27 story to reflect that Bristol Myers owns full rights to therapy Abecma; the error had also appeared in two previous versions of the story) By Siddhi Mahatole (Reuters) -The U.S. Food and Drug Administrati... Full story

Yahoo Finance • 7 days ago

The Hackett Group® Announces Winners of the 2025 Hackett Innovation Awards

Bosch, BT International, Johnson & Johnson, McCormick & Company, Inc., Roche Turkiye, and Schneider Electric Recognized for Their Innovative Use of AI MIAMI, June 30, 2025--(BUSINESS WIRE)--The Hackett Group, Inc. (NASDAQ: HCKT), a leadin... Full story

Yahoo Finance • 8 days ago

Oncolytics Biotech® Appoints Former Ambrx Executive as Chief Business Officer to Drive Business Development Strategy

SAN DIEGO and CALGARY, Alberta, June 30, 2025 /CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the appointment of Andrew Aromando as C... Full story

Yahoo Finance • 8 days ago

Vicarious Surgical adds two new directors to board

WALTHAM, Mass. - Surgical robotics company Vicarious Surgical Inc. (NYSE:RBOT), currently valued at $1.59 billion and showing strong momentum with a 27.61% gain last week, announced Monday the election of Fuad Ahmad and Joseph Doherty to i... Full story

Yahoo Finance • 10 days ago

Johnson & Johnson’s (JNJ) IMAAVY Demonstrates Superior gMG Control

Johnson & Johnson (NYSE:JNJ) is one of the 12 stocks that will make you rich in 10 years. On June 23, J&J announced new data from an indirect treatment comparison (ITC) study. The data show that the company’s drug, IMAAVY (nipocalimab-aahu... Full story

Yahoo Finance • 10 days ago

Validea Detailed Fundamental Analysis - JNJ

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks... Full story

Yahoo Finance • 11 days ago

How PepsiCo, Johnson & Johnson, And Skyworks Solutions Can Put Cash In Your Pocket

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. PepsiCo, Joh... Full story

Yahoo Finance • 11 days ago

Why JNJ Is a Long-Term Winner

Johnson & Johnson (NYSE:JNJ) is one of the Best Wide Moat Dividend Stocks to Invest in.Why JNJ Is a Long-Term Winner A smiling baby with an array of baby care products in the foreground. Johnson & Johnson (NYSE:JNJ) is a long-established... Full story

Yahoo Finance • 11 days ago

Guru Fundamental Report for JNJ

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Shareholder Yield Investor model based on the published strategy of Meb Faber. This strategy looks fo... Full story

Yahoo Finance • 12 days ago

Retinitis Pigmentosa Research Report 2025: $25+ Bn Market Opportunities and Strategies to 2034 - Gene Therapy Poised as Fastest Growing Treatment Segment, Strategic Collaborations Drive Advancements

Company Logo The global retinitis pigmentosa market, valued at $11.31 billion in 2024, is expected to grow to $25.87 billion by 2034, driven by gene therapy advancements, aging populations, and strategic industry collaborations. North Ame... Full story

Yahoo Finance • 12 days ago

Johnson & Johnson CAR T Therapy Shows 80% Response in Lymphoma Trial

Johnson & Johnson (NYSE:JNJ) ranks among the top stocks for an early retirement portfolio. On June 13, Johnson & Johnson (NYSE:JNJ) announced that patients with relapsed or refractory large B-cell lymphoma (LBCL) showed strong response rat... Full story